Pharsight

1. Veltassa patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP09748557A	2016-04-21	Teva Pharmaceutical Industries Ltd	Patent maintained as amended
EP09748557A	2016-04-18	Hexal AG	Patent maintained as amended

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8337824	VIFOR PHARMA	Linear polyol stabilized polyfluoroacrylate compositions	May, 2030 (6 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8475780	VIFOR PHARMA	Ion binding polymers and uses thereof	Mar, 2024 (6 months from now)
US8778324	VIFOR PHARMA	Ion binding polymers and uses thereof	Mar, 2024 (6 months from now)
US8287847	VIFOR PHARMA	Ion binding polymers and uses thereof	Mar, 2024 (6 months from now)
US8889115	VIFOR PHARMA	Ion binding polymers and uses thereof	Mar, 2024 (6 months from now)
US10485821	VIFOR PHARMA	Ion binding polymers and uses thereof	Mar, 2024 (6 months from now)
US7556799	VIFOR PHARMA	Ion binding polymers and uses thereof	Feb, 2025 (1 year, 5 months from now)
US8216560	VIFOR PHARMA	Ion binding polymers and uses thereof	Mar, 2027 (3 years from now)
US8282913	VIFOR PHARMA	Ion binding polymers and uses thereof	May, 2027 (3 years from now)
US8147873	VIFOR PHARMA	Methods and compositions for treatment of ion imbalances	Jun, 2028 (4 years from now)
US9925212	VIFOR PHARMA	Potassium-binding agents for treating hypertension and hyperkalemia	Oct, 2033 (10 years from now)
US9492476	VIFOR PHARMA	Potassium-binding agents for treating hypertension and hyperkalemia	Oct, 2033 (10 years from now)
US11123363	VIFOR PHARMA	Potassium-binding agents for treating hypertension and hyperkalemia	Oct, 2033 (10 years from now)